A Patient With Metastatic Lung Adenocarcinoma Harboring Concurrent EGFR L858R, EGFR Germline T790M, and PIK3CA Mutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer
作者： Philip E. Lammers , Christine M. Lovly , Leora Horn
关键词:
摘要: Mutational testing has moved to the forefront as an integral component in management of patients with non-small cell lung cancer (NSCLC). Currently there are three targeted therapies (erlotinib, afatinib, and crizotinib) approved by Food Drug Administration (FDA) treat specific genetic abnormalities NSCLC. As mutational screening expands include a greater number genes, it will become more difficult interpret results, particularly if mutations found multiple genes or that not actionable at time testing. This case report summarizes diagnosis treatment patient NSCLC harbored potentially targetable ‘driver’ mutations. We also discuss current NCCN guidelines for inherent difficulties interpretation results when single gene across genes.
sci-hub.se 参考文章(21)
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Oliver Gautschi, Chantal Pauli, Klaus Strobel, Astrid Hirschmann, Gert Printzen, Stefan Aebi, Joachim Diebold, A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Journal of Thoracic Oncology. ,vol. 7, pp. e23- e24 ,(2012) , 10.1097/JTO.0B013E3182629903
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
J. De Grève, E. Teugels, C. Geers, L. Decoster, D. Galdermans, J. De Mey, H. Everaert, I. Umelo, P. In’t Veld, D. Schallier, Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu Lung Cancer. ,vol. 76, pp. 123- 127 ,(2012) , 10.1016/J.LUNGCAN.2012.01.008
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan, Amy Donahue, Sean R Downing, Garrett M Frampton, Lazaro Garcia, Frank Juhn, Kathy C Mitchell, Emily White, Jared White, Zac Zwirko, Tamar Peretz, Hovav Nechushtan, Lior Soussan-Gutman, Jhingook Kim, Hidefumi Sasaki, Hyeong Ryul Kim, Seung-il Park, Dalia Ercan, Christine E Sheehan, Jeffrey S Ross, Maureen T Cronin, Pasi A Jänne, Philip J Stephens, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nature Medicine. ,vol. 18, pp. 382- 384 ,(2012) , 10.1038/NM.2673
Carmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, Laura Boldrini, Marielle I. Gallegos-Ruiz, Ilaria Bernardini, Roberto Incensati, Romano Danesi, Federico Cappuzzo, Godefridus J. Peters, Gabriella Fontanini, Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients Journal of Thoracic Oncology. ,vol. 6, pp. 395- 396 ,(2011) , 10.1097/JTO.0B013E3182059A6F
Zengliu Su, Dora Dias-Santagata, MarKeesa Duke, Katherine Hutchinson, Ya-Lun Lin, Darrell R. Borger, Christine H. Chung, Pierre P. Massion, Cindy L. Vnencak-Jones, A. John Iafrate, William Pao, A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer The Journal of Molecular Diagnostics. ,vol. 13, pp. 74- 84 ,(2011) , 10.1016/J.JMOLDX.2010.11.010
Philip C. Mack, William S. Holland, Rebekah A. Burich, Randeep Sangha, Leslie J. Solis, Yueju Li, Laurel A. Beckett, Primo N. Lara, Angela M. Davies, David R. Gandara, EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. Journal of Thoracic Oncology. ,vol. 4, pp. 1466- 1472 ,(2009) , 10.1097/JTO.0B013E3181BBF239
Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Rita Chiari, Vincenzo Minotti, Renato Colella, Dario Giuffrida, Francesca Romana Tofanetti, Annamaria Siggillino, Antonella Flacco, Elisa Baldelli, Daniela Iacono, Maria Grazia Mameli, Antonio Cavaliere, Lucio Crinò, Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 6, pp. 707- 715 ,(2011) , 10.1097/JTO.0B013E31820A3A6B